Arthrosi Therapeutics Stock / BioTech & PharmaFounded: 2018

Arthrosi Therapeutics, founded in 2018, is a clinical-stage biotech company focused on the development of therapy for gout and chronic kidney disease. The company offers research and development services in the clinical stage, specifically targeted at treatments for gout and chronic kidney disease, with the goal of facilitating healthcare professionals in delivering effective uric acid reduction and the healing of joint damage brought on by tophi. Arthrosi Therapeutics is headquartered in San Diego, California.

Register for Details

For more details on financing and valuation for Arthrosi Therapeutics, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in


Enterprise Value (based on primary financings)

Powered by Forge Data
Enterprise Value

View Enterprise Value for Arthrosi Therapeutics.

Register Today

Arthrosi Therapeutics investors also invested in these private companies

Reichstein Biotech
Guangrun Health Industry
Heda Ventures
Linghang Ventures
Changrong Capital
FengHe Fund Management
LTS Capital Advisors
Viva Biotech
JMCR Family Office


Management Team

Litain Yeh Ph.D
Co-Founder & Chief Executive Officer
Philip Moody
Chief Financial Officer
Shunqi Yan Ph.D
Co-Founder & Chief Operating Officer
Robert Keenan MD
Chief Medical Officer

Other companies like Arthrosi Therapeutics in the BioTech & Pharma sector

Last Round Est. Valuation
Last Round Est. Valuation
Last Round Est. Valuation
Last Round Est. Valuation
Last Round Est. Valuation
Last Round Est. Valuation
Last Round Est. Valuation

News Highlights

Arthrosi wins $75m in Series D financing
Arthrosi Therapeutics, a biotechnology company specialising in gout treatment, has successfully secured $75m in Series D financing. Led by Guangrun Health Industry, the financing round was supported by several investors, including ApicHope Pharmaceuticals subsidiary Reichstein Biotech.
Updated on: Oct 3, 2023


Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.